CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← BridgeBio Pharma, Inc. (BBIO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

BridgeBio Pharma, Inc. (BBIO)

Pharmaceutical Preparations · market cap $13.0B · as of 2026-10-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-27
PDUFA
Pipeline
4
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
BridgeBio Pharma (BBIO) is a ~$13.1B market-cap company (~195.5M shares at ~$67.13) with a pipeline in our data spanning amyloidosis (acoramidis, Phase 3; AG10, Phase 2 in familial ATTR-CM) and autosomal dominant hypocalcemia (encaleret, Phase 3). The nearest high-importance event is a 2026-11-27 PDUFA date for BBP-418, preceded by estimated Q3 earnings on 2026-11-04. Reported revenue rose from $9M in 2023 to $222M in 2024 and $502M in 2025, while the company still lost $733M in 2025 and carries $1.975B of net debt.
The catalyst path
  • 2026-11-27PDUFA · BBP-418imp 9/10
  • 2027-02-04PDUFA · Infigratinibimp 9/10
  • 2027-05-08PDUFA · Encaleretimp 8/10
Pipeline
AssetPhaseIndication
AG10Phase 2Familial ATTR-CM (ATTRm-CM, or FAC)
AcoramidisPhase 3Amyloidosis
EncaleretPhase 3Autosomal Dominant Hypocalcemia (ADH)
InfigratinibPhase 3Achondroplasia
Price & technical context
3-month
-6.2%
6-month
+10.0%
12-month
+16.0%
52-wk range
$63.30–$90.17
vs 50-day MA
+8.2%
vs 200-day MA
+4.5%
Realized vol
43.9%
Max drawdown
-29.8%

Daily closes through 2026-11-20. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for BBIO (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.